Epic launches program to ‘unify’ clinical research with care delivery
At launch, Epic said it plans to unite each of the stakeholders through the use of a single system, the Life Sciences program. According to the company, providers around the world use Epic to conduct more than 100,000 active research studies, involving approximately 4.7 million patients.
With the Life Sciences program, Epic will focus on matching providers with clinical trials tailored to the makeup of their patient populations, which the company says will be available at launch. Beyond that, Alan Hutchison, vice president, population, health and payer strategy at Epic, told Outsourcing-Pharma that the company’s R&D team is currently working on the next pieces of the roadmap. of the Life Sciences program.
The release says Epic has four other goals beyond clinical trial matching: making clinical trials accessible, increasing clinical trial efficiency, supporting clinicians with point-of-care information, and providing research. specially designed for suppliers to assess whether a test is correct. for them.
The overall goal, according to Hutchison, is to create, “A unified infrastructure that connects all aspects of healthcare, including providers, patients, payers, specialty diagnostic labs, life science companies, and more, can support higher quality care, a more consistent healthcare experience and faster medical innovation.”
Epic said the Life Sciences program would expand access to clinical trials, including to underrepresented communities, which is a major talking point in the industry. Hutchison clarified that improving access can be viewed as a two-step process, in terms of study sites and individual patients.
In terms of study sites, clinical trial matching allows sponsors to connect with provider organizations to treat diverse patient populations. The result for participating provider sites will be to receive more clinical trial opportunities tailored to their patients, Hutchison noted. Epic is also working to reduce technical and personnel barriers to entry for study site participation, expanding access to providers and patients.
For patients, Hutchison said, “Providers can share study opportunities with patients directly through MyChart, which more than 155 million US patients use today to manage their care. We are further enhancing this patient-centric workflow by creating a single landing point in MyChart where patients can browse ongoing studies in the Epic community that match their unique genomic profiles, medical history, and research preferences. .
Additionally, providers will be able to see real-time alerts in the workflow that indicate when their patients’ clinical data indicates they are eligible for a clinical trial.